Details for Patent: 10,905,694

✉ Email this page to a colleague

Which drugs does patent 10,905,694 protect, and when does it expire?

Patent 10,905,694 protects JYNARQUE and SAMSCA and is included in two NDAs.

This patent has thirty patent family members in twenty-four countries.

Summary for Patent: 10,905,694

Patent landscape, scope, and claims:

Title:	Pharmaceutical solid preparation comprising benzazepines and production method thereof
Abstract:	The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-t- etrahydro-1H-benzoazepine and/or salt thereof; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; and (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 .mu.m, and a 90% cumulative particle diameter of 100 to 200 .mu.m.
Inventor(s):	Nakagawa; Shinsuke (Osaka, JP), Suzuki; Kai (Osaka, JP), Mukai; Tadashi (Osaka, JP)
Assignee:	OTSUKA PHARMACEUTICAL CO., LTD. (Tokyo, JP)
Application Number:	12/665,642
Patent Claim Types: see list of patent claims	Formulation; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 10,905,694

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441-001	Apr 23, 2018		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441-002	Apr 23, 2018		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441-003	Apr 23, 2018		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,905,694

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2007-163551	Jun 21, 2007

PCT Information
PCT Filed	June 20, 2008	PCT Application Number:	PCT/JP2008/061686
PCT Publication Date:	December 24, 2008	PCT Publication Number:	WO2008/156217

International Family Members for US Patent 10,905,694

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	067077	⤷ Subscribe
Austria	E489944	⤷ Subscribe
Australia	2008264445	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.